Unlike FGFR1 and FGFR3—firmly implicated as oncogenic drivers in tumor invasion and proliferation [128–130]—wild-type FGFR2b often acts in a tumor-suppressive manner to promote differentiation or apoptosis [131–136], with FGFR2b downregulation mirroring FGFR1 upregulation during progression or epithelial-mesenchymal transition (EMT) [137–142]. This evidence concerns the gene FGFR1 and neoplasm.